The [experimental] designs were different, but the end results were very similar and highly complementary, says Ian Wilson, co-author on the Science paper and a structural and computational biologist at the Scripps Research Institute in San Diego, California. Its a promising first step, and it's very exciting to see this research come to fruition. Authors of both studies say the next step is expanding protection to other strains of influenza, namely H3 and H7.
It does not make any sense to start out every new drug and vaccine with an N>100 experiment.
Can anything be sadder than work left unfinished? Yes, work never begun.